| Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
|---|
| 08/11/2005 | WO2005073247A1 Amino acid and peptide conjugates of amiloride and methods of use thereof |
| 08/11/2005 | WO2005072779A2 Growth factor-binding compounds attached to a calixarene |
| 08/11/2005 | WO2005072778A2 Use of amino-oxy functional groups in the preparation of vaccines conjugates |
| 08/11/2005 | WO2005072777A2 Conjugates of amyloid proteins as vaccines for amyloid-related diseases |
| 08/11/2005 | WO2005072776A2 Liposomal formulations of the antineoplastic agents |
| 08/11/2005 | WO2005072745A2 Aqueous solutions comprising prednisolone and a cyclodextrin derivative |
| 08/11/2005 | WO2005072737A1 Injectable euthanasia compositions that include a taste aversive agent |
| 08/11/2005 | WO2005072736A2 Stable gabapentin compositions |
| 08/11/2005 | WO2005072710A2 Drugs and gene carrier particles that rapidly move through mucous barriers |
| 08/11/2005 | WO2005072707A1 Nanoparticle-containing composition and process for producing the same |
| 08/11/2005 | WO2005072701A1 Compositions for localized therapy of the eye, comprising preferably triamcinolone acetonide and hyaluronic acid |
| 08/11/2005 | WO2005072679A2 Adjuvant formulation containing an oily emulsion with jojoba oil |
| 08/11/2005 | WO2005072479A2 Polymer-bound antibody concer therapeutic agent |
| 08/11/2005 | WO2005072343A2 Aqueous pharmaceutical compositions 2,6-diisopropylphenol (propofol) and their use |
| 08/11/2005 | WO2005072334A2 Photoresponsive hydrogels |
| 08/11/2005 | WO2005072141A2 Peptide inhibitors of rhoa signaling |
| 08/11/2005 | WO2005072088A2 Immunotherapy compositions, method of making and method of use thereof |
| 08/11/2005 | WO2005072061A2 Conjugates for cancer therapy and diagnosis |
| 08/11/2005 | WO2005054279A8 Delivery peptides, their constructs with active agents and use |
| 08/11/2005 | WO2005051902A8 Modified mscl protein channel |
| 08/11/2005 | WO2005048919A3 Preventative effects of morinda citrifolia on mammary breast cancer |
| 08/11/2005 | WO2005042023B1 Composite material comprising a porous semiconductor impregnated with an organic substance |
| 08/11/2005 | WO2005041871A3 Apparatus and method for enhancing transdermal drug delivery |
| 08/11/2005 | WO2005037245A3 A multiple route medication for the treatment of rhinitis and asthma |
| 08/11/2005 | WO2004112837A8 PREPARATION FOR EXTERNAL PERCUTANEOUS ADMINISTRATION CONTAINING NON-STEROIDAL ANTI-INFLAMMATORY DRUG AND INTERLEUKIN-1α PRODUCTION INHIBITOR |
| 08/11/2005 | WO2004028457A3 PHARMACEUTICAL COMPOSITION FOR IMPROVED ADMINISTRATION OF HIV gp41-DERIVED PEPTIDES, AND ITS USE IN THERAPY |
| 08/11/2005 | WO2003077836A3 Compositions and methods for the detection, diagnosis and therapy of hematological malignancies |
| 08/11/2005 | WO2003075846A3 Uses of monoclonal antibody 8h9 |
| 08/11/2005 | US20050176922 Water soluble, non-peptidic polymer covalently attached to a Diels-Alder bicyclic or tricyclic imide ring; chemical intermediates |
| 08/11/2005 | US20050176871 Thermoplastic Elastomer-Based Solid Emulsions |
| 08/11/2005 | US20050176765 For therapy of glaucoma, dementia such as Alzheimer's disease and vascular dementia, depression, attention deficit disorder, sleep disorder, schizophrenia, pain, ischemia; -[1-[1-(3-Thienoyl)piperidin-4-yl]piperidin-4-yl]-1,3-dihydro-2H-benzimidazol-2-one |
| 08/11/2005 | US20050176673 guanin-9-yl, adenin-9-yl, 2,6-diaminopurin-9-yl, 2-aminopurin-9-yl or their 1-deaza, 3-deaza, or 8-aza compounds, or cytosin-1-yl - ethoxymethanephosphonic acid derivatives, used to treat osteoporosis and other disorders of bone metabolism, cancer, or viral infections |
| 08/11/2005 | US20050176672 Use of cationic lipids to generate anti-tumor immunity |
| 08/11/2005 | US20050176666 Each double stranded siNA sequence is between 18 and 23 nucleotides, directs gene cleavage and also has a complementary antisense region; antiinflammatory agents; respiratory system disorders |
| 08/11/2005 | US20050176664 RNA interference mediated inhibition of cholinergic muscarinic receptor (CHRM3) gene expression using short interfering nucleic acid (siNA) |
| 08/11/2005 | US20050176663 RNA interference mediated inhibition of protein tyrosine phosphatase type IVA (PRL3) gene expression using short interfering nucleic acid (siNA) |
| 08/11/2005 | US20050176657 Anthelmintic oral homogeneous veterinary pastes |
| 08/11/2005 | US20050176650 ethylenediaminetetraacetic acid (EDTA) or salt as first stabilizer, and monothioglycerol (MTG) or glutathione as second stabilizer; psychosis, agitation, pain, migraine headache, nausea, vomiting, itching, hypertension, benign prostatic hypertrophy, excess gastrointestinal secretions, sleeplessness |
| 08/11/2005 | US20050176627 increasing the hematocrit of an individual while maintaining the tissue protective activities of endogenous erythropoietin through the administration of a pharmaceutical compound containing chemically modified long acting erythropoietin. Also disclosed are the new erythropoietins |
| 08/11/2005 | US20050176621 Crystalline compositions for controlling blood glucose |
| 08/11/2005 | US20050176619 N-[[1-[[2-(diethylamino)ethyl]amino]-7-methoxy-9-oxothioxanthen-4-yl]-methyl]formamide, or a pharmaceutically acceptable acid-addition salt thereof, and to the method of use thereof in the treatment of tumors and cancers. |
| 08/11/2005 | US20050176616 Adjustment of pH; purification using ion exchange resin; controlling viscosity and temperature |
| 08/11/2005 | US20050176128 Method for assembling subunits into capsoids |
| 08/11/2005 | US20050176108 Physiologically active polypeptide conjugate having prolonged in vivo half-life |
| 08/11/2005 | US20050176025 RNA interference mediated inhibition of B-cell CLL/Lymphoma-2 (BCL-2) gene expression using short interfering nucleic acid (siNA) |
| 08/11/2005 | US20050176024 chemically synthesized double stranded siNA that directs cleavage of EGFR such as HER1, HER2, HER3 or HER4; diagnosis or treatment of cancer for example |
| 08/11/2005 | US20050175991 Using fluid comprising bacteria lysing virus bacteria as tool in cleaning fruits and vegatables |
| 08/11/2005 | US20050175763 Phosphatidyl serine, phosphatidyl choline and similar compounds; food for tube feeding; health-giving, performance-enhancing or disease-preventing (eg diabetes) |
| 08/11/2005 | US20050175748 Antimicrobial envelopes |
| 08/11/2005 | US20050175724 Composition for modulating at least one physiological reaction or inducing an immune response in human or animal after oral administration; for intestinal delivery of a physiologically active agent, a neutralizing agent, an inhibitor of digestive enzymes, an uptake increasing agent; synergistic |
| 08/11/2005 | US20050175709 Therapeutic microparticles |
| 08/11/2005 | US20050175706 Sustained release oral formulations |
| 08/11/2005 | US20050175704 Polyacrylamide hydrogel as a soft tissue filler endoprosthesis |
| 08/11/2005 | US20050175702 Contains magnetic and/or metallic colloids; produced by suspension polymerization |
| 08/11/2005 | US20050175692 Pharmaceutical formulation comprising melatonin |
| 08/11/2005 | US20050175682 Polyethyleneglycol-modified lipid compounds and uses thereof |
| 08/11/2005 | US20050175679 Controlled release formulations |
| 08/11/2005 | US20050175676 Patch |
| 08/11/2005 | US20050175675 Film-shaped, dissolvable preparations for active substance release and method for the production thereof |
| 08/11/2005 | US20050175672 Particulate plant sterol compositions |
| 08/11/2005 | US20050175668 Lapachone delivery systems, compositions and uses related thereto |
| 08/11/2005 | US20050175647 Compositions for topical application having androgenic actions |
| 08/11/2005 | US20050175644 Preparation for oxidation-sensitive compounds and method for making same |
| 08/11/2005 | US20050175642 Stable loratadine spill resistant formulation |
| 08/11/2005 | US20050175641 Homogenous liquid blend of hydrophilic polyvinyl alcohol, hydroxypropylmethyl cellulose, hydroxypropyl cellulose , polyvinyl pyrollidone, carbomer, maleic anhydride-methyl vinyl ether decadiene cross polymer and/or hydroxypropylguar; and hydrophobic ethyl cellulose; anti-onychomycoses agents; acne |
| 08/11/2005 | US20050175640 Cyclodextrin and adrenocortical steroid dissolved in aqueous solution; dextran or pullulan; mixture with xyloglucan, trehalose, laminaran, pectin, and krestin; grape sugar, mutan, lentinan, sodium chloride, and/or potassium chloride; side effect reduction; psoriasis, atopic diseases |
| 08/11/2005 | US20050175636 Containing stabilized neurotoxin as analgesic and skin penetration enhancing agent; inflammation and/or pain reduction |
| 08/11/2005 | US20050175629 Helicobacter pylori vaccination |
| 08/11/2005 | US20050175628 Chinese herb medicine composition in the form of jelly |
| 08/11/2005 | US20050175620 Multivalent platform molecules comprising high molecular weight polyethylene oxide |
| 08/11/2005 | US20050175619 Methods of producing antibody conjugates |
| 08/11/2005 | US20050175611 Storage stability, heat resistance; such as cetuximab combined with glycine and polyoxyethylene sorbitan monooleate in aqueous pH 5.5 citrate buffer |
| 08/11/2005 | US20050175603 Reduced-viscosity concentrated protein formulations |
| 08/11/2005 | US20050175597 For easy administration and storage stability |
| 08/11/2005 | US20050175592 Storage stability; use of bulking agents, cryoprotectants and lyoprotectants imparts desired properties that allow both lyophilized and liquid adenovirus formulations to be stored at 4 degrees C. for up to 6 months and retain an infectivity between 60-100% of the starting infectivity |
| 08/11/2005 | US20050175588 Contain one or more recombinant molecule(s) expressed on a cellular surface and incorporated and/or associated with a particle that does not require cellular entry for delivery; for stimulation of biological processes, inactivation of inhibitory factors, scavenging and/or detoxifying |
| 08/11/2005 | US20050175583 Making vector compositions that mimic the functionality of components of the immune system especially antigen-presenting cell (APC) element of the immune synapse; vaccination |
| 08/11/2005 | US20050175582 Non-antigenic toxin-conjugate and fusion protein of internalizing receptor system |
| 08/11/2005 | US20050175573 terblock polymer of ethylene oxide-propylene oxide-ethylene oxide terminated via carbamate or urea bond formed by mono or diisocyanate compounds; chain extesion; cosmetic, prosthetic inserted into an organ of human body; reversible gelation |
| 08/11/2005 | US20050175572 water-soluble copolymer obtained by radical copolymerization of acrylamide and/or methacrylamide and other water-soluble alpha, beta -ethylenically unsaturated compounds which are copolymerizable therewith; cosmetics, medicine, soaps, cream, lotion, hair shapmpoo, conditioner |
| 08/11/2005 | US20050175571 Prepared by melt processing a hydrophobic polymer includes repeating pyrrolidone/alkylene groups containing 10 or more carbon atoms, a hydrophilic polymer including polyacrylic acid, maleic acid-methyl vinyl ether copolymer, starch, cellulose, polyvinyl alcohol, dextrans/yclodextrin; cosmetics; skin |
| 08/11/2005 | US20050175555 2,4,6,8,10,12,14-hexadecaheptaenol in cyclodextrins; antitumor , antiinflammatory, antiaging, antiprolifrative agent, antioxident; activation of free radical production, cardiovascular disorders, atherosclerosis; cosmetic and pharmaceutical use |
| 08/11/2005 | US20050175542 System, formulation, kit and method for tagging colonic residue in an individual |
| 08/11/2005 | US20050175541 Enhanced drug delivery |
| 08/11/2005 | US20050172954 Methods and systems for operating an aerosol generator |
| 08/11/2005 | DE202004020433U1 Capsule for investigation and treatment of the digestive tract comprises a housing which completely surrounds a permanent magnet, and incorporates at least one space for at least one medicament |
| 08/11/2005 | DE102004063612A1 Gel former, useful for making salt-containing products for mineral supplementation and deacidification in humans or animals, comprises at least two different natural polymers |
| 08/11/2005 | DE102004028415B4 Dermales oder transdermales therapeutisches System enthaltend eine Abdeckfolie mit Barrierewirkung The dermal or transdermal therapeutic system comprising a cover sheet with barrier effect |
| 08/11/2005 | CA2554729A1 Polymer-bound antibody cancer therapeutic agent |
| 08/11/2005 | CA2553674A1 Growth factor-binding compounds and methods of use |
| 08/11/2005 | CA2548992A1 Immunotherapy compositions, method of making and method of use thereof |
| 08/10/2005 | EP1561469A1 Activated Protein C Formulations |
| 08/10/2005 | EP1561459A1 Pharmaceutical hard capsule containing inorganic substance |
| 08/10/2005 | EP1561458A1 Rapidly disintegrable solid preparation |
| 08/10/2005 | EP1560854A2 Taxanes covalently bounded to hyaluronic acid or hyaluronic acid derivatives |
| 08/10/2005 | EP1560611A1 Self-folding polymer microparticles |
| 08/10/2005 | EP1560600A1 Method for the selective and quantitative functionalization of immunoglobulin fab fragments, conjugate compounds obtained with the same and compositions thereof |
| 08/10/2005 | EP1560599A1 Prodrugs built as multiple self-elimination-release spacers |
| 08/10/2005 | EP1560596A1 Use of multi-specific, non-covalent complexes for targeted delivery of therapeutics |
| 08/10/2005 | EP1560577A2 Pharmaceutical compositions and methods of using taxane derivatives |